[1]邢瑞青,彭道荣,刘　杨.血清CA199，KL-6和PIVKA-Ⅱ水平联合检测在胰腺癌诊断中的应用价值分析[J].现代检验医学杂志,2021,36(05):100-104.[doi:10.3969/j.issn.1671-7414.2021.05.022]
　XING Rui-qing,PENG Dao-rong,LIU Yang.Application Value of Combined Detection of Serum CA199,KL-6 andPIVKA -Ⅱ Levels in the Diagnosis of Patients with Pancreatic Cancer[J].Journal of Modern Laboratory Medicine,2021,36(05):100-104.[doi:10.3969/j.issn.1671-7414.2021.05.022]
点击复制

血清CA199，KL-6和PIVKA-Ⅱ水平联合检测在胰腺癌诊断中的应用价值分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第36卷
期数:
2021年05期
页码:
100-104
栏目:
论　著
出版日期:
2021-10-14

文章信息/Info

Title:
Application Value of Combined Detection of Serum CA199,KL-6 andPIVKA -Ⅱ Levels in the Diagnosis of Patients with Pancreatic Cancer
文章编号:
1671-7414（2021）05-100-05
作者:
邢瑞青; 彭道荣; 刘　杨
（空军军医大学第一附属医院临床实验研究所，西安 710032）
Author(s):
XING Rui-qing;  PENG Dao-rong;  LIU Yang
（Research Institute of Clinical Laboratory Medicine of PLA , Xijing Hospital, Air Force MedicalUniversity, Xi’an 710032, China）
关键词:
糖类抗原199; 异常凝血酶原; 涎液化糖链抗原; 胰腺癌
分类号:
R735.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2021.05.022
文献标志码:
A
摘要:
目的　探讨血清糖类抗原199（CA199）、异常凝血酶原（PIVKA-Ⅱ）、涎液化糖链抗原（KL-6）对胰腺癌的诊断价值。方法　采用电化学发光法与化学发光法测定2020年1月～5月来空军军医大学第一附属医院就诊的49例胰腺癌患者，44例胰腺炎患者及42例健康对照者血清CA199，PIVKA-Ⅱ和KL-6水平，观察上述指标在各组患者中的表达水平，分析该三项联合检测对于胰腺癌的诊断价值。结果　胰腺癌组血清CA199，PIVKA-Ⅱ和KL-6水平与健康对照组、胰腺炎组对比，差异均具有统计学意义（U=263.000，Z=-6.098; U=1 006.500，Z=-5.010; U=299.500，Z=-5.808和U=482.000，Z=-4.587；U=1 972.000，Z=-2.540；U=667.500，Z=-3.159，均P<0.05）。胰腺炎组血清CA199，PIVKA-Ⅱ和KL-6水平与健康对照组对比，差异无统计学意义(U=693.000，Z=-1.996；U=576.000，Z=-3.090；U=482.500，Z=-3.815，均P>0.05)。CA199，PIVKA-Ⅱ和KL-6曲线下面积与参考曲线下面积相比，差异均具有统计学意义（均P<0.05），CA199的曲线下面积最大。CA199，PIVKA-Ⅱ和KL-6三项联合检测敏感度、特异度、阴性预测值和准确度分别为85.70%，76.50%，77.40%和74.90%。与单项检测对比，CA199，PIVKA-Ⅱ和KL-6三项联合检测对胰腺癌诊断的敏感度、特异度、阴性预测值（NPV）及准确度的差异均具有统计学意义（χ2分别为42.110，37.220，17.940和21.030，均P <0.05）。结论　CA199,PIVKA-Ⅱ和KL-6对胰腺癌的诊断具有重要临床价值，CA199，PIVKA-Ⅱ和KL-6联合检测可提高胰腺癌的诊断敏感度，特异度及准确度。
Abstract:
Objective　To investigate the diagnostic value of serumCA199, PIVKA- Ⅱ and KL-6 in pancreatic cancer.Methods　Serum levels of CA199,PIVKA- Ⅱ and KL-6 in 49 patients with pancreatic cancer,44 patients with pancreatitis and42 healthy controls were measured by electro chemiluminescence and chemiluminescence from January to May 2020 ,observedthe expression of the three indicators in pancreatic cancer group , pancreatitis group and healthy controls, and analyzed thediagnostic value of the combined detection of three indicatiors. Results　Compared with the pancreatitis group and healthycontrols group, the differences of the serm levels of CA199, PIVKA- Ⅱ and KL-6 in pancreatic cancer group were statisticallysignificant（U=263.000，Z=-6.098; U=1006.500，Z=-5.010; U=299.500，Z=-5.808 and U=482.000，Z=-4.587；U=1972.000，Z=-2.540；U=667.500，Z=-3.159, all P<0.05）. Compared with the healthy controls group, the differences of theserm levels of CA199, PIVKA- Ⅱ and KL-6 in the pancreatitis group were not statistically significant(U=693.000，Z=-1.996；U=576.000，Z=-3.090; U=482.500，Z=-3.815, all P>0.05).The area under ROC curve of CA199 was largest.Comparedwith reference curve, the areas of CA199, PIVKA- Ⅱ and KL-6 under ROC curve all had significant statistical differences（all P<0.05）. The sensitivity, specificity, NPV and accuracy of the combined detection of CA199 , PIVKA - Ⅱ and KL-6 were85.70%, 76.50%, 77.40% and 74.90%, respectively. Compared with the single test,the sensitivity, specificity, NPV and accuracyof the combined detection of CA199, PIVKA - Ⅱ and KL-6 in the diagnosis of pancreatic cancer were statistically significant（χ2=42.110，37.220，17.940 and 21.030，all P<0.05）. Conclusion　CA199, PIVKA- Ⅱ and KL-6 detections could benefitthe diagnosis of pancreatic cancer. The diagnosis efficacy was elevated when the combined detection of CA199 ,PIVKA - Ⅱ andKL-6 was used to diagnize pancreatic cancer.

参考文献/References:

[1] METTU N B, ABBRUZZESE J L. Clinical insightsinto the biology and treatment of pancreatic cancer[J].Journal of Oncology Practice, 2016, 12(1): 17-23.
[2] RAWLA P, SUNKARA T, GADUPUTI V.Epidemiology of pancreatic cancer: global trends,etiology and risk factors[J]. World Journal of Oncology,2019, 10(1): 10-27.
[3] CHEN Wanqing, SUN Kexin, ZHENG Rongshou, etal. Cancer incidence and mortality in China, 2014[J].Chinese Journal of Cancer Research, 2018, 30(1): 1-12.
[4] 汪明琼，杨秀珍，汤丽平．胰腺癌生物标志物研究进展[J]. 现代医药卫生,2018,34(14):2185-2188.WANG Mingqiong,YANG Xiuzhen,TANG Liping.Research progress on biomarkers of pancreaticcancer [J]. Journal of Modern Medicine Health, 2018,34(14):2185-2188.
[5] LIEBMAN H A, FURIE B C, TONG M J, et al. Desgamma-carboxy(abnormal)prothrombin as a serummarker of primary hepato-cellular carcinomal[J]. NewEngland Journal of Medicine, 1984, 310(22): 1427-1431.
[6] 李娟, 尚彦彦, 席红利, 等. 评价血清CA125, CA199,CA153 联合检测对肺癌诊断及分期的临床价值[J].中国医药科学,2017,7(13):101-103.LI Juan,SHANG Yanyan,XI Hongli,et al. Evaluationof clinical value of combined detection of serumCA125,CA199 and CA153 in diagnosis andstaging of lung cancer [J]. China Medicine andPharmacy,2017,7(13):101-103.
[7] 傅冰洁，俞霞，李付贵，等．CA199 联合血清异常凝血酶原在胰腺癌早期诊断中的临床价值[J]．国际医药卫生导报，2020,26(7):973-976.FU Bingjie,YU Xia,LI Fugui,et al. The clinicalvalue of CA199 combined with abnormal serumprothrombin in the early diagnosis of pancreatic cancer[J]. International Medicine and Health GuidanceNews,2020,26(7):973-976.
[8] 杨柳, 闫欢, 石燕, 等. 晚期胰腺癌患者血清CA125,CA199 水平与肝转移的关系[J]. 中国实验诊断学,2017,21(5):770-773.YANG Liu,YAN Huan,SHI Yan,et al. Relationshipbetween serum CA125 ,CA199 levels and liver metastasisin patients with advanced pancreatic cancer [J]. ChineseJournal of Laboratory Diagnosis,2017,21(5):770-773.
[9] 林文科，吴吉芳，郑志昂．多种肿瘤标志物在胰腺癌中的诊断价值及相关性研究[J]．中国免疫学杂志,2017, 33(1):120-125.LIN Wenke,WU Jifang,ZHENG Zhiang. Diagnosticvalue and correlation of multiple tumor markers inpancreatic cancer [J]. Chinese Journal of Immunology,2017, 33(1):120-125.
[10] ZHANG Yun, JIANG Lihua, SONG Lin. Meta-analysisof diagnostic value of serum Carbohydrate antigen 199 inpancreatic cancer[J]. Minerva Medica, 2016, 107(1): 62-69.
[11] THOMAS C. Risk factors, biomarker and imagingtechniques used for pancreatic cancer screening[J].Chinese Clinical Oncology, 2017, 6(6): 61.
[12] 中华医学会肿瘤学分会早诊早治学组. 中华医学会肿瘤学分会胰腺癌早诊早治专家共识[J]. 临床肝胆病杂志,2020,36(12):2675-2680.Early Diagnosis and Treatment Group the OncologyCommittee of Chinese Medical Association. Expertconsensus of oncology committee of Chinese MedicalAssociation in early diagnosis and treatment ofpancreatic cancer [J]. Journal of Clinical Hepatology,2020,36(12):2675-2680.
[13] CAVIGLIA G P, RIBALDONE D G, ABATE M L,et al. Performance of protein induced by vitamin Kabsence or antagonist-II assessed by chemiluminescenceenzyme immunoassay for hepatocellular carcinomadetection: a meta-analysis[J]. Scandinavian Journal ofGastroenterology, 2018, 53(6): 734-740.
[14] TARTAGLIONE S, PECORELLA I, ZARRILLO S R,et al. Protein induced by vitamin K absence II (PIVKAII)as a potential serological biomarker in pancreaticcancer: a pilot study[J]. Biochemia Medica, 2019,29(2): 020707.
[15] 李晓君， 赖韶钦， 谭俊青． 胰腺癌肿瘤标志物对胰腺癌早期诊断的研究进展[J]. 按摩与康复医学,2018,9(3):12-14.LI Xiaojun,LAI Shaoqin,TAN Junqing. Researchprogress of tumor markers for early diagnosis ofpancreatic cancer [J]. Chinese Manipulation &Rehabilitation Medicine,2018,9(3):12-14.
[16] BALMA?A M, DURAN A, GOMES C, et al. Analysisof sialyl-Lewis X on MUC5AC and MUC1 mucins inpancreatic cancer tissues[J]. International Journal ofBiological Macromolecules, 2018, 112: 33-45.
[17] 许焕丽, 刘晓卉, 林秀坤. KL-6mucin 糖链表达与胰腺癌转移的相关性研究[C].2015 医学前沿论坛暨第十四届全国肿瘤药理与化疗学术会议摘要汇编. 沈阳， 2015:251.XU Huanli,LIU Xiaohui,LIN Xiukun.Relationship betweenKl-6mucin glycochain expression and metastasisof pancreatic cancer[C]. Summary of 2015 MedicalFrontier Forum and the 14th National Conference onCancer Pharmacology and Chemotherapy.Shenyang,2015:251.
[18] 张典，高兴春，姜凤良，等. 黏蛋白在肿瘤诊断和治疗中的作用[J]. 中国老年学杂志,2016,36(9):2275-2277.ZHANG Dian,GAO Xingchun,JIANG Fengliang,et al.The role of mucin in the diagnosis and treatment of tumor[J]. Chinese Journal of Gerontology, 2016,36(9):2275-2277.
[19] XU Huanli, ZHAO Xin, ZHANG Keming, et al.Inhibition of KL-6/MUC1 glycosylation limitsaggressive progression of pancreatic cancer[J]. WorldJournal of Gastroenterology, 2014, 20(34): 12171-12181.
[20] 董静肖，崔世伟，杨晓欢，等．血清异常凝血酶原在胰腺癌诊断中的应用价值研究[J]．中国实验诊断学,2020,24(6):922-925.DONG Jingxiao,CUI Shiwei,YANG Xiaohuan,etal. The application value of serum PIVKA-II in thediagnosis of pancreatic cancer [J]. Chinese Journal ofLaboratory Diagnosis,2020,24(6):922-925.
[21] 赵晓娇，姚玮艳，袁耀宗．血清KL-6 水平在胰腺癌诊断与鉴别诊断中的价值[J]．中华胰腺病杂志,2011,11(3):155-158.ZHAO Xiaojiao,YAO Weiyan,YUAN Yaozong.Diagnostic and differential value of elevated serumKL-6 levels in pancreatic cancer [J]. Chinese Journal ofPancreatology, 2011,11(3):155-158.

相似文献/References:

[1]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
　ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[2]周淑燕,卓传尚,柳丽娟,等.PIVKA-II和AFP联合检测对原发性肝癌的诊断价值[J].现代检验医学杂志,2017,32(01):69.[doi:10.3969/j.issn.1671-7414.2017.01.019]
　ZHOU Shu-yan,ZHUO Chuan-shang,LIU Li-juan,et al.Clinical Value of Serum PIVKA-lI and AFP Detection for Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2017,32(05):69.[doi:10.3969/j.issn.1671-7414.2017.01.019]

备注/Memo

备注/Memo:
作者简介：邢瑞青（1982-）, 女, 硕士，主治医师，研究方向：临床免疫学检验及临床相关疾病的研究，E-mail:xrqing210b@163.com。
通讯作者：刘杨（1988-），女，硕士，主管技师，研究方向：肿瘤诊断与免疫，E-mail: 315612101@qq.com。
更新日期/Last Update: 1900-01-01